RxDoctor Payments Data

Ammar Ali, MD

Psychiatry · Dearborn, MINPI 1669797627

Payments from drug & device makers

$1,277in general payments, 2019–2025

Across 46 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$306
  • Teva Pharmaceuticals USA, Inc.$265
  • TMS Neurohealth Centers Inc.$142
  • Johnson & Johnson$131
  • Indivior Inc.$116
  • Otsuka America Pharmaceutical, Inc.$101
  • plus $216 from 3 others

What the payments were for

  • Food & beverage$1,17592%
  • Education$1018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,277 in reported general payments places this provider in the 80th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$23,761
Medicare patients
84
Services billed
262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate44$144,341
Abilify MaintenaAripiprazole13$36,834
Paliperidone ErPaliperidone18$16,041
Aripiprazole58$8,363
TrintellixVortioxetine Hydrobromide14$7,210
Clozapine OdtClozapine16$7,100
Clozapine35$5,821
Divalproex Sodium ErDivalproex Sodium46$3,797
Fluphenazine Decanoate23$2,360
Oxcarbazepine46$2,147
Atomoxetine Hcl19$1,832
Ziprasidone Hcl13$1,371
Lurasidone Hcl21$1,267
Mirtazapine51$1,064
Carbamazepine ErCarbamazepine13$1,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$131$144,34144 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$101$36,83413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →